article thumbnail

STAT+: Hospitals struggle to make money on CAR-T cancer therapies, but their fortunes may change

STAT

WASHINGTON — Hospitals for years have complained that Medicare pays so little for CAR-T cancer treatments that they sometimes lose money administering the incredibly expensive treatments. CAR-T uses the body’s own immune system to kill cancerous cells. Continue to STAT+ to read the full story…

Hospitals 177
article thumbnail

STAT+: Brigham creates institute focused on immunology with record $100 million gift

STAT

Brigham and Women’s Hospital will launch a new institute focused on immunology and inflammation, thanks to a $100 million gift, the largest in the hospital’s history. The institute will also investigate the aging of the immune system and immune dysfunction in cancer.

Immunity 241
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Galapagos, in makeover mode, strikes deal to make CAR-T therapies at blood centers across U.S.

STAT

Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make.

Hospitals 269
article thumbnail

Researchers identify genetic changes responsible for rare childhood immune disorders

Pharma Times

Affecting the immune system, various forms of SCID are estimated to affect one in 75,000 to 100,000 newborns

Immunity 141
article thumbnail

CDC advisers endorse RSV monoclonal antibody for infants, high-risk young children

STAT

A panel of advisers to the Centers for Disease Control and Prevention unanimously voted Thursday to recommend wide use among infants and some high-risk children of an antibody designed to protect against RSV , the country’s leading cause of infant hospitalization. Read the rest…

Immunity 246
article thumbnail

STAT+: Pharma’s ambitious antibiotic venture fund makes another investment

STAT

million to BioVersys, which is developing an antibiotic to combat a type of bacteria that affects people with compromised immune systems and is increasingly responsible for infections in hospitalized patients. In its latest move, the fund is providing $7.5

Hospitals 239
article thumbnail

STAT+: Medicare would have saved $3.7 billion on Part B drugs if inflationary rebates were around in a recent three-year period

STAT

More specifically, 70 of the 93 top-selling drugs covered by the Medicare Part B program – which are typically pricier medicines that are administered by physicians or in hospitals – between 2018 and 2020 would have been subject to inflationary rebates each year, according to the analysis published in JAMA.